Sanofi wins EU approval for Dupixent in chronic urticaria

Sanofi secured European Union approval for Dupixent as the first medication against chronic spontaneous urticaria in children.

Published 31sem17 sources✓ ConfirmedNotableupdated 14sem
Lire en français
≈ 22s

The fact

This regulatory authorization expands the therapeutic indications of the treatment and strengthens the French laboratory's commercial position.

Dupixent represents an expansion of Sanofi's pharmaceutical portfolio in inflammatory diseases.

17 sources — click a link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.

Story timeline

Apr 13Sanofi wins EU approval for Dupixent in chronic urticariathis article
Union européenne · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →
Follow topic →
Auto-synthesis from 17 media sources · identified on April 13, 2026
← Back to home
Discover

Read more

All marches →